SIP
NAGE

Stoneridge Investment Partners’s Niagen Bioscience NAGE Stock Holding History

Stoneridge Investment Partners’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$223K Hold
50,641
– – 0.16% 94
2025
Q4 		$322K Buy
+50,641
New +$352K 0.22% 85

Other funds holding NAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SW
SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Stoneridge Investment Partners's NAGE Position: Q1 2026 in Review

Stoneridge Investment Partners held its Niagen Bioscience (NAGE) position steady in Q1 2026 at 50,641 shares worth $223K. The position accounts for 0.16% of the portfolio, ranked #94.

Stoneridge Investment Partners first reported a position in NAGE in Q4 2025 and has held it in 2 quarters since. The position peaked at $322K in Q4 2025. 143 funds tracked by Wall St. Rank hold NAGE as of Q1 2026.

  • Stoneridge Investment Partners held 50,641 shares of Niagen Bioscience worth $223K as of Q1 2026.
  • Stoneridge Investment Partners left its Niagen Bioscience share count unchanged in Q1 2026.
  • Niagen Bioscience made up 0.16% of Stoneridge Investment Partners's portfolio in Q1 2026, its #94 holding.
  • Stoneridge Investment Partners first reported a position in Niagen Bioscience in Q4 2025 and has held it in 2 quarters since.
  • Stoneridge Investment Partners's Niagen Bioscience position peaked at $322K in Q4 2025.
  • 143 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2026.

Based on Stoneridge Investment Partners's 13F filing for Q1 2026, filed 6 May 2026.